Source:http://linkedlifedata.com/resource/pubmed/id/17018857
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2007-1-24
|
| pubmed:abstractText |
The JAK2-V617F mutation occurs in about 50% of patients with myelofibrosis and might be a reliable marker to monitor residual disease after allogeneic stem cell transplantation. We describe a new, highly sensitive (>or= 0.01%) real-time polymerase chain reaction (PCR) to monitor and quantify V617F-JAK2-positive cells after dose-reduced allogeneic stem cell transplantation. After 22 allogeneic stem cell transplantation procedures in 21 JAK2-positive patients with myelofibrosis, 78% became PCR negative. In 15 of 17 patients (88%), JAK2 remained negative after a median follow-up of 20 months. JAK2 negativity was achieved after a median of 89 days after allograft (range, 19-750 days). A significant inverse correlation was seen for JAK2 positivity and donor-cell chimerism (r:-0.91, P<.001). Four of 5 patients who never achieved JAK2 negativity fulfilled during the entire follow-up all criteria for complete remission recently proposed by the International Working Group, suggesting a major role for JAK2 measurement to determine depths of remission. In one case, residual JAK2-positive cells were successfully eliminated by donor lymphocyte infusion. In conclusion, allogeneic stem cell transplantation after dose-reduced conditioning induces high rates of molecular remission in JAK2-positive patients with myelofibrosis, and quantification of V617F-JAK2 mutation by real-time PCR allows the detection of minimal residual disease to guide adoptive immunotherapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
109
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1316-21
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:17018857-Adult,
pubmed-meshheading:17018857-Aged,
pubmed-meshheading:17018857-Female,
pubmed-meshheading:17018857-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:17018857-Humans,
pubmed-meshheading:17018857-Janus Kinase 2,
pubmed-meshheading:17018857-Male,
pubmed-meshheading:17018857-Middle Aged,
pubmed-meshheading:17018857-Mutation, Missense,
pubmed-meshheading:17018857-Neoplasm, Residual,
pubmed-meshheading:17018857-Primary Myelofibrosis,
pubmed-meshheading:17018857-Remission Induction,
pubmed-meshheading:17018857-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:17018857-Sensitivity and Specificity,
pubmed-meshheading:17018857-Survival Analysis,
pubmed-meshheading:17018857-Transplantation, Homologous,
pubmed-meshheading:17018857-Transplantation Chimera
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.
|
| pubmed:affiliation |
Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, and Department of Hematology/Oncology, University Hospital Regensburg, Germany. nkroeger@uke.uni-hamburg.de
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|